Review finds unreliable evidence for berberine in polycystic ovary syndrome
All four eligible trials raised serious research-integrity concerns, so reliable conclusions about benefits could not be drawn.
Low evidenceReviewInterpret with caution
Medical disclaimer: This article summarizes research findings and is for informational purposes only. It is not medical advice.
Editorial illustration — not from the study.
Researchers searched four medical databases for randomized controlled trials of berberine in women with polyendocrine metabolic ovarian syndrome. The search found four eligible trials from China, India, and Pakistan, with 89 to 129 participants per trial. The trials compared berberine or a berberine phytosome with options including metformin, placebo, myo-inositol, or lifestyle interventions over 12 weeks.
The trials reported improvements in measures such as insulin resistance, blood fats, and androgen-related markers. However, the review team identified concerns including missing trial registration, implausible recruitment timelines, small author groups, and possible duplication of data. The researchers received no responses when they contacted the trial authors, so they considered the reported findings unreliable and did not combine them in a quantitative analysis.
The question reviewed
The researchers conducted a systematic review following PRISMA guidance and registered it prospectively. They searched MEDLINE, EMBASE, the Cochrane Library, and CINAHL from database inception through October 2025 for English-language randomized controlled trials involving women with polyendocrine metabolic ovarian syndrome and standardized berberine preparations. Two reviewers independently assessed eligibility and research integrity using the RIGID framework and TRACT checklist. The review identified four trials involving 452 participants; no new human participants were enrolled for this review.
Key conclusions
All four eligible trials were independently rated as having a high risk of compromised integrity. The concerns included absent registration, implausible study timelines, limited authorship, and potential duplication of findings. The reported trials described improvements in insulin resistance, lipid profiles, and androgen markers, but because the trials were excluded for these integrity concerns, the review authors said those results could not be considered reliable. No quantitative synthesis was performed, and the review did not establish berberine's efficacy.
Who this is relevant to
The review is most directly relevant to questions about standardized berberine preparations in women with polyendocrine metabolic ovarian syndrome, previously called polycystic ovary syndrome. Its conclusions do not establish effects in people without this condition, in men, in children, or for preparations and uses not studied in the trials. Because the underlying trial results were considered unreliable, the findings should not be interpreted as a dependable estimate of berberine's benefits or risks for any patient group.
The significance
This review highlights that the apparent benefits reported in earlier evidence summaries may depend on trials whose research conduct and reporting cannot be adequately verified. It also shows why the number of studies alone does not determine how dependable a medical conclusion is. The work does not demonstrate that berberine is ineffective; rather, it indicates that the currently identified evidence cannot reliably determine its effects in women with polyendocrine metabolic ovarian syndrome.
Limitations & evidence assessment
Only four eligible trials were found, leaving a small evidence base and preventing a meaningful sensitivity analysis. The review included only English-language studies because of resource constraints, so relevant studies in other languages may have been missed. The underlying trials also had small sample sizes, short 12-week follow-up periods, open-label designs, and differences in berberine formulations. Because all four trials were excluded, the review could not conduct the planned quantitative synthesis or provide a precise estimate of benefit or harm.
Why this evidence level: Although this was a prospectively registered systematic review, all four eligible randomized trials were judged to have a high risk of compromised research integrity and were excluded from evidence synthesis. Therefore, the review could not provide reliable evidence about berberine's effects.
Evidence levels are editorial estimates derived from study metadata — they are not clinical appraisals.
// Source
Advances in Therapy · 2026 · DOI: 10.1007/s12325-026-03799-7
This systematic review examined randomized human trials of concurrent chemotherapy and radiation for locally advanced head and neck, cervical, esophageal, and non-small-cell lung cancers. Across the included trials, combined treatment was reported to provide better overall survival than radiation alone, but it also caused more severe short-term side effects. The review did not provide enough information in its abstract to show how many trials or patients were included.
Researchers pooled results from seven human studies comparing multiple-staged with single-stage removal and reconstruction of congenital melanocytic nevi, sometimes called congenital moles. Staged surgery was associated with fewer major wound complications and recurrences, as well as slightly shorter and narrower scars, but the studies did not find a clear difference in cosmetic or overall patient satisfaction.
A cluster-randomized human study in 210 adults with recently detected stage 1 hypertension in Uzbekistan compared salt-sensitivity testing followed by assigned medication choices with conventional management. After 12 weeks, more participants in the testing-guided group reached the study's blood pressure target, although the study was small, short, and conducted in only three primary care centers.
